Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market segmentation, By Product Type (Robotic Systems, Instruments and Accessories), End User (Hospitals, Cath Labs and Others) - Industry Trends and Forecast to 2033

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Size

• The Asia-Pacific robot assisted percutaneous coronary intervention (PCI) market size was valued at USD 928.5 Million in 2025 and is expected to reach USD 3443.05 Million by 2033, at a CAGR of 17.80% during the forecast period
• The market growth is largely fueled by the growing prevalence of cardiovascular diseases, rising demand for minimally invasive procedures, and technological advancements in robotic catheterization and imaging systems, leading to increased adoption of robot-assisted PCI in hospitals and cardiac centers
• Furthermore, rising need for enhanced procedural accuracy, reduced radiation exposure, and improved patient outcomes is accelerating the uptake of Robot Assisted Percutaneous Coronary Intervention (PCI) solutions, thereby significantly boosting the industry's growth

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Analysis

• Robot-assisted PCI systems, offering advanced precision, reduced radiation exposure, and enhanced control during coronary interventions, are increasingly becoming vital components of modern interventional cardiology due to their ability to improve accuracy, optimize patient outcomes, and support minimally invasive procedure adoption across hospitals and cardiac centers
• The escalating demand for robot-assisted PCI is primarily fueled by the rising global burden of cardiovascular diseases, growing preference for minimally invasive procedures, technological advancements in robotic catheters and imaging systems, and increasing adoption of automation in catheterization labs to improve workflow efficiency and clinical consistency
• China dominated the robot assisted percutaneous coronary intervention (PCI) market with the largest revenue share of 35% in 2025, driven by rapid adoption of robotic surgical systems, strong government support for medical technology advancement, rising cardiovascular disease prevalence, and significant investments by hospitals in AI-enabled interventional platforms
• India is expected to be the fastest-growing market in the Asia-Pacific region, projected to grow at a CAGR of 15.8% from 2026 to 2033, fueled by increasing cardiac disease cases, rapid expansion of tertiary care hospitals, government initiatives promoting advanced robotic-assisted procedures, and growing demand for minimally invasive interventions across metropolitan healthcare facilities
• The Robotic Systems segment dominated the largest market revenue share of 67.5% in 2025, driven by the rapid technological advancements supporting precision navigation, reduced radiation exposure, and improved patient outcomes during PCI procedures

Report Scope and Robot Assisted Percutaneous Coronary Intervention (PCI) Market Segmentation 

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Trends

Growing Shift Toward High-Precision Robotic Navigation and Imaging Integration

• A significant and accelerating trend in the robot-assisted percutaneous coronary intervention (PCI) market is the deepening integration of high-precision robotic navigation systems with advanced intravascular imaging technologies such as IVUS, OCT, and FFR. This convergence is enhancing procedural accuracy, operator safety, and workflow efficiency across the region’s leading cardiovascular centers

  • For instance, next-generation PCI robotic systems deployed across Japan, South Korea, Singapore, and China now incorporate real-time imaging synchronization, automated catheter manipulation, and enhanced lesion visualization, enabling operators to perform complex coronary interventions with greater consistency and reduced physical strain. Several hospitals in Asia-Pacific have already documented improvements in stent placement accuracy following robotic–imaging integration

• The increasing adoption of remote operation capabilities, allowing cardiologists to navigate guidewires and deploy stents from a radiation-protected workstation, is rapidly transforming the region’s interventional cardiology landscape. This not only reduces occupational hazards associated with prolonged X-ray exposure but also enhances ergonomics for cardiologists performing high-volume procedures
• The seamless connection of robotic PCI systems with digital cath lab ecosystems, including procedural workflow software, EHRs, and imaging consoles, allows operators to control multiple procedural elements through a unified interface. This integration supports smoother data flow, improved decision-making, and more standardized outcomes across complex interventions
• This trend toward highly automated, precision-driven robotic systems is reshaping clinical expectations in Asia-Pacific, driving hospitals to adopt platforms that enhance patient safety, reduce variability across procedures, and support minimally invasive cardiovascular care. Major manufacturers are responding by introducing systems with refined haptic feedback, improved catheter stability, and faster device exchange mechanisms
• The rising demand for robotic PCI systems is further supported by growing investments in specialized cardiac centers, regional clinical trials, and government-backed programs aimed at strengthening cardiovascular care infrastructure, particularly in China, India, Japan, and South Korea

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Dynamics

Driver

Growing Need Due to Rising Cardiovascular Disease Burden and Adoption of Minimally Invasive Technologies

• The increasing prevalence of coronary artery disease (CAD) across Asia-Pacific, coupled with the rising demand for minimally invasive cardiovascular procedures, is a significant driver for the accelerating adoption of robotic PCI technologies in the region

  • For instance, in April 2025, several leading cardiovascular centers in Asia-Pacific announced expansions of robotic-assisted interventional cardiology programs, integrating next-generation robotic systems equipped with improved imaging and AI-guided navigation to enhance procedural efficiency. Such strategic advancements in the region’s interventional cardiology infrastructure are expected to drive robust market growth

• As clinicians face more complex lesions and increasing procedural volume, robotic PCI systems offer benefits such as reduced radiation exposure, enhanced precision in stent placement, improved operator ergonomics, and greater control during challenging anatomies, providing a compelling upgrade over traditional manual PCI
• Furthermore, the growing adoption of advanced cath lab technologies—including IVUS, OCT, and fractional flow reserve (FFR) systems—supports the integration of robotic platforms that can seamlessly coordinate with these modalities for optimized procedural outcomes
• The ability of robotic PCI systems to provide remote operation capabilities, enable precise device manipulation, and improve standardization in complex interventions is accelerating demand across high-volume hospitals and cardiac specialty centers. In addition, the increasing availability of training programs and user-friendly robotic interfaces further contributes to market expansion

Restraint/Challenge

Concerns Regarding High Costs and Limited Technical Expertise

• Despite the rapid technological progress, concerns surrounding the high capital cost of robotic PCI systems and the associated maintenance expenses pose a significant challenge to broader adoption, especially among mid-sized healthcare facilities in emerging Asia-Pacific economies

  • For instance, reports highlighting the limited penetration of high-cost robotic interventional systems in developing Asia-Pacific regions have slowed overall adoption, as many hospitals prioritize cost-effective alternatives before investing in advanced robotic platforms

• Addressing these challenges requires improving cost-efficiency, enhancing reimbursement support, and providing extensive training for interventional cardiologists. Vendors emphasize features such as workflow optimization, long-term cost reduction through fewer complications, and reduced radiation exposure to justify investment. In addition, limited availability of skilled personnel trained in robotic PCI can be a barrier in several Asia-Pacific markets
• While training programs and structured certification pathways are expanding, the perceived complexity of integrating robotic systems into existing cath lab workflows continues to hinder widespread adoption, especially among hospitals lacking advanced imaging infrastructure
• Overcoming these challenges through greater affordability, wider availability of training, and improved interoperability with existing cath lab technologies will be vital for long-term and sustained market growth

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Scope

The market is segmented on the basis of product type and end user.

• By Product Type

On the basis of product type, the Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) market is segmented into Robotic Systems and Instruments & Accessories. The Robotic Systems segment dominated the largest market revenue share of 67.5% in 2025, driven by the rapid technological advancements supporting precision navigation, reduced radiation exposure, and improved patient outcomes during PCI procedures. Hospitals and cath labs across Japan, China, South Korea, and Australia increasingly prefer robotic systems due to their ability to facilitate complex interventions with higher accuracy and operator safety. The strong presence of AI-enabled workflow automation and integration with advanced imaging technologies reinforces system adoption. Growing prevalence of coronary artery disease, rising elderly populations, and the intensifying focus on minimally invasive procedures further contribute to segment leadership. Favorable government initiatives to upgrade cardiac care infrastructure also influence strong uptake. Improved surgeon ergonomics and reduced fatigue associated with robotic PCI In addition support broad usage across tertiary hospitals in the region.

The Instruments & Accessories segment is anticipated to witness the fastest CAGR of 15.8% from 2026 to 2033, fueled by the recurrent need for consumables required in every PCI procedure and the expanding installed base of robotic systems across Asia-Pacific. Increasing procedure volumes, rising physician adoption of catheter robotics, and heightened emphasis on precision tools drive strong demand for guide catheters, robotic wires, disposable cassettes, and catheter-control components. As hospitals increasingly shift toward advanced robotic workflows, the need for compatible accessories grows steadily. Product upgrades from OEMs, improved integration with imaging systems, and enhanced durability of disposable instruments also accelerate growth. In addition, rising investments from regional hospitals in consumables procurement programs and service contracts contribute to continued expansion. Growing training programs for robotic PCI across emerging markets further increase utilization of robotic accessories.

• By End User

On the basis of end user, the Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) market is segmented into Hospitals, Cath Labs, and Others. The Hospitals segment accounted for the largest market revenue share of 54.1% in 2025, driven by the concentration of advanced cardiac care infrastructure, higher patient throughput, and the availability of skilled interventional cardiologists. Hospitals prefer robotic PCI systems for their ability to reduce variability in procedures, improve accuracy, and mitigate radiation exposure to staff and patients. Increasing hospital investments in catheterization laboratories and robotic platforms enhance adoption rates. Rising incidence of cardiovascular diseases and expanding insurance coverage across Asia-Pacific further strengthen demand for robotic PCI within hospital settings. Many hospitals are upgrading to hybrid OR and integrated imaging systems, pushing forward robotic PCI adoption. Government-supported modernization programs also contribute to dominance. Higher clinical success rates and shorter recovery times make robotic PCI attractive to hospital networks aiming to boost their cardiac care reputation.

The Cath Labs segment is expected to witness the fastest CAGR of 16.4% from 2026 to 2033, driven by the growing trend toward standalone catheterization laboratories and increased need for minimally invasive cardiovascular interventions. Cath labs, particularly in China and India, are expanding rapidly due to rising cardiovascular patient loads and continuous capacity additions. The specialization and high procedure frequency typical of cath labs make robotic PCI systems highly attractive for improving procedural consistency and reducing exposure to fluoroscopy. Growing private cardiology centers in urban regions are investing heavily in robotic solutions to differentiate service offerings. Enhanced affordability of mid-scale robotic platforms and improved integration with intravascular imaging tools accelerate segment growth. In addition, increased training availability for interventional cardiologists in robotic techniques bolsters adoption.

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Regional Analysis

• The Asia-Pacific robot assisted percutaneous coronary intervention (PCI) market is poised for significant growth, projected to achieve the fastest CAGR during the forecast period of 2026 to 2033. This growth is driven by increasing urbanization, rising disposable incomes, and technological advancements in countries like China and India
• Expansion of healthcare infrastructure, including tertiary care hospitals and cardiac centers, is fueling the adoption of advanced robotic-assisted procedures. The rising prevalence of cardiovascular diseases has created strong demand for minimally invasive interventions, which reduce procedural risks and shorten patient recovery times
• Government initiatives to promote modern healthcare technologies and robotic-assisted procedures are further accelerating market growth. Investments in hospital infrastructure, along with increasing awareness among cardiologists and patients regarding the benefits of robotic-assisted interventions, are contributing to the widespread adoption of these systems

India Robot Assisted Percutaneous Coronary Intervention (PCI) Market Insight

India robot assisted percutaneous coronary intervention (PCI) market is expected to be the fastest-growing market in the Asia-Pacific region, with a projected CAGR of 15.8% from 2026 to 2033. The growth is fueled by the rising number of cardiac disease cases and the increasing demand for minimally invasive interventions across metropolitan healthcare facilities. The rapid expansion of tertiary care hospitals and specialty cardiac centers is supporting market development. Government initiatives promoting advanced robotic-assisted procedures, along with investments in modern catheterization labs, are accelerating adoption. Collaborations with global robotic system providers and enhanced training programs for interventional cardiologists are improving technical expertise, which, combined with growing awareness about procedural safety and precision benefits, is boosting market penetration. Investments in hospital infrastructure are also enhancing the availability of robotic-assisted PCI systems across both urban and semi-urban areas.

China Robot Assisted Percutaneous Coronary Intervention (PCI) Market Insight

China robot assisted percutaneous coronary intervention (PCI) market accounted for the largest market revenue share in Asia-Pacific in 2025, holding 35% of the market. This dominance is driven by the rapid adoption of robotic surgical systems, strong government support for healthcare technology advancement, and the high prevalence of cardiovascular diseases. Significant investments by hospitals in robotic-assisted PCI platforms have expanded access to these advanced procedures. Domestic manufacturers producing cost-effective robotic PCI systems have improved affordability and availability across both public and private healthcare sectors. Additionally, increasing training programs and awareness initiatives for cardiologists are supporting the adoption of robotic-assisted interventions throughout major Chinese cities, further solidifying the country’s leadership in the regional market.

Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market Share

The Robot Assisted Percutaneous Coronary Intervention (PCI) industry is primarily led by well-established companies, including:

• Intuitive Surgical (U.S.)

• Robocath (France)

• Stereotaxis (U.S.)

• Catheter Precision (U.S.)

• Hansen Medical (U.S.)

• CARMAT (France)

• Siemens Healthineers (Germany)

• Abbott Laboratories (U.S.)

• Philips Healthcare (Netherlands)

• Terumo Corporation (Japan)

• Asahi Intecc (Japan)

• MicroPort Scientific (China)

• Shanghai MicroPort (China)

• Cardiobot (China)

• Remedics (U.S.)

Latest Developments in Asia-Pacific Robot Assisted Percutaneous Coronary Intervention (PCI) Market

• In February 2021, Siemens Healthineers expanded the footprint of robotic vascular interventions by introducing the CorPath GRX system (from Corindus Vascular Robotics) in India — enabling robotic-assisted coronary and peripheral vascular interventions in a country with high cardiovascular disease burden
• In May 2022, Corindus showcased CorPath GRX at the major interventional cardiology congress EuroPCR — including live robotic-assisted PCI cases and presentation of initial post‑market data from the NAVIGATE study, underscoring growing clinical adoption and interest in robotic PCI worldwide
• In May 2025, a large-scale real-world analysis published at the conference TCT 2025 confirmed that robotic-assisted PCI is safe and effective: among 1,734 robotic PCI procedures, clinical success rates were high (~97 %), even with complex lesions — signaling maturity of robotic PCI technologies in routine practice

SKU-44770